DiaMedica Therapeutics (DMAC) announced the completion of a productive pre-IND meeting with the FDA for a planned study evaluating DM199 in preeclampsia. The company said minutes from the meeting affirmed the FDA’s request for one additional non-clinical study in a rabbit model, with results expected by Q2 2026. DiaMedica also noted that in an ongoing Phase 2 investigator-sponsored trial in South Africa, over 30 women have been dosed, with interim data showing encouraging safety and efficacy signals.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting
- Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress
- Microsoft initiated, Home Depot downgraded: Wall Street’s top analyst calls
- DiaMedica Therapeutics initiated with an Overweight at Cantor Fitzgerald
- DiaMedica Therapeutics Reports Q3 2025 Financial Results